Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Sep 1;100(5):1282–1293. doi: 10.1172/JCI119642

Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.

M Kavallaris 1, D Y Kuo 1, C A Burkhart 1, D L Regl 1, M D Norris 1, M Haber 1, S B Horwitz 1
PMCID: PMC508306  PMID: 9276747

Abstract

The treatment of advanced ovarian cancer with taxol is hindered by the development of drug resistance. The cellular target for taxol is the microtubule that is stabilized by the drug. Taxol preferentially binds to the beta subunit of tubulin of which there are six distinct isotypes in mammalian cells. We have used highly specific oligonucleotides and polymerase chain reaction to analyze expression of all six beta-tubulin genes. Human lung cancer cells (A549) were selected in 12 and 24 nM taxol resulting in cell lines that were 9- and 17-fold resistant, respectively. These cells displayed an altered ratio of classes I, II, III, and IVa beta-tubulin isotypes. Ovarian tumors, seven untreated primary and four taxol- resistant tumor-bearing ascites, displayed significant increases (P < 0.005) in classes I (3.6-fold), III (4.4-fold), and IVa (7.6-fold) isotypes in the taxol-resistant samples as compared with untreated primary ovarian tumors. The increased expression appears to be related to the resistance phenotype, as the basal levels of the class III and IVa isotypes in the untreated tumors were extremely low. This is the first report of altered expression of specific beta-tubulin genes in taxol-resistant ovarian tumors and we propose that the latter may play a role in clinical resistance to taxol.

Full Text

The Full Text of this article is available as a PDF (385.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander J. E., Hunt D. F., Lee M. K., Shabanowitz J., Michel H., Berlin S. C., MacDonald T. L., Sundberg R. J., Rebhun L. I., Frankfurter A. Characterization of posttranslational modifications in neuron-specific class III beta-tubulin by mass spectrometry. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4685–4689. doi: 10.1073/pnas.88.11.4685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bell D. R., Gerlach J. H., Kartner N., Buick R. N., Ling V. Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J Clin Oncol. 1985 Mar;3(3):311–315. doi: 10.1200/JCO.1985.3.3.311. [DOI] [PubMed] [Google Scholar]
  3. Bordow S. B., Haber M., Madafiglio J., Cheung B., Marshall G. M., Norris M. D. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res. 1994 Oct 1;54(19):5036–5040. [PubMed] [Google Scholar]
  4. Bourhis J., Goldstein L. J., Riou G., Pastan I., Gottesman M. M., Bénard J. Expression of a human multidrug resistance gene in ovarian carcinomas. Cancer Res. 1989 Sep 15;49(18):5062–5065. [PubMed] [Google Scholar]
  5. Burgoyne R. D., Cambray-Deakin M. A., Lewis S. A., Sarkar S., Cowan N. J. Differential distribution of beta-tubulin isotypes in cerebellum. EMBO J. 1988 Aug;7(8):2311–2319. doi: 10.1002/j.1460-2075.1988.tb03074.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Burke D., Gasdaska P., Hartwell L. Dominant effects of tubulin overexpression in Saccharomyces cerevisiae. Mol Cell Biol. 1989 Mar;9(3):1049–1059. doi: 10.1128/mcb.9.3.1049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cabral F. R., Brady R. C., Schibler M. J. A mechanism of cellular resistance to drugs that interfere with microtubule assembly. Ann N Y Acad Sci. 1986;466:745–756. doi: 10.1111/j.1749-6632.1986.tb38456.x. [DOI] [PubMed] [Google Scholar]
  8. Cabral F., Barlow S. B. Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly. FASEB J. 1989 Mar;3(5):1593–1599. doi: 10.1096/fasebj.3.5.2646163. [DOI] [PubMed] [Google Scholar]
  9. Cannistra S. A. Cancer of the ovary. N Engl J Med. 1993 Nov 18;329(21):1550–1559. doi: 10.1056/NEJM199311183292108. [DOI] [PubMed] [Google Scholar]
  10. Chomczynski P., Qasba P. K. Alkaline transfer of DNA to plastic membrane. Biochem Biophys Res Commun. 1984 Jul 18;122(1):340–344. doi: 10.1016/0006-291x(84)90480-7. [DOI] [PubMed] [Google Scholar]
  11. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  12. Cole S. P., Sparks K. E., Fraser K., Loe D. W., Grant C. E., Wilson G. M., Deeley R. G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994 Nov 15;54(22):5902–5910. [PubMed] [Google Scholar]
  13. Cowan N. J., Dudley L. Tubulin isotypes and the multigene tubulin families. Int Rev Cytol. 1983;85:147–173. doi: 10.1016/s0074-7696(08)62372-4. [DOI] [PubMed] [Google Scholar]
  14. Derry W. B., Wilson L., Jordan M. A. Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry. 1995 Feb 21;34(7):2203–2211. doi: 10.1021/bi00007a014. [DOI] [PubMed] [Google Scholar]
  15. Derry W. B., Wilson L., Khan I. A., Luduena R. F., Jordan M. A. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Biochemistry. 1997 Mar 25;36(12):3554–3562. doi: 10.1021/bi962724m. [DOI] [PubMed] [Google Scholar]
  16. Gilbert J., Norris M. D., Haber M., Kavallaris M., Marshall G. M., Stewart B. W. Determination of N-myc gene amplification in neuroblastoma by differential polymerase chain reaction. Mol Cell Probes. 1993 Jun;7(3):227–234. doi: 10.1006/mcpr.1993.1033. [DOI] [PubMed] [Google Scholar]
  17. Greenberger L. M., Lothstein L., Williams S. S., Horwitz S. B. Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cell lines. Proc Natl Acad Sci U S A. 1988 Jun;85(11):3762–3766. doi: 10.1073/pnas.85.11.3762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Haber M., Burkhart C. A., Regl D. L., Madafiglio J., Norris M. D., Horwitz S. B. Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J Biol Chem. 1995 Dec 29;270(52):31269–31275. doi: 10.1074/jbc.270.52.31269. [DOI] [PubMed] [Google Scholar]
  19. Holmes F. A., Walters R. S., Theriault R. L., Forman A. D., Newton L. K., Raber M. N., Buzdar A. U., Frye D. K., Hortobagyi G. N. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991 Dec 18;83(24):1797–1805. doi: 10.1093/jnci/83.24.1797-a. [DOI] [PubMed] [Google Scholar]
  20. Holzmayer T. A., Hilsenbeck S., Von Hoff D. D., Roninson I. B. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst. 1992 Oct 7;84(19):1486–1491. doi: 10.1093/jnci/84.19.1486. [DOI] [PubMed] [Google Scholar]
  21. Horwitz S. B., Cohen D., Rao S., Ringel I., Shen H. J., Yang C. P. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr. 1993;(15):55–61. [PubMed] [Google Scholar]
  22. Jaffrézou J. P., Dumontet C., Derry W. B., Durán G., Chen G., Tsuchiya E., Wilson L., Jordan M. A., Sikic B. I. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncol Res. 1995;7(10-11):517–527. [PubMed] [Google Scholar]
  23. Johnson S. W., Ozols R. F., Hamilton T. C. Mechanisms of drug resistance in ovarian cancer. Cancer. 1993 Jan 15;71(2 Suppl):644–649. doi: 10.1002/cncr.2820710224. [DOI] [PubMed] [Google Scholar]
  24. Jordan M. A., Toso R. J., Thrower D., Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9552–9556. doi: 10.1073/pnas.90.20.9552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kavallaris M., Leary J. A., Barrett J. A., Friedlander M. L. MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors. Cancer Lett. 1996 Apr 19;102(1-2):7–16. doi: 10.1016/0304-3835(96)04143-2. [DOI] [PubMed] [Google Scholar]
  26. Khan I. A., Ludueña R. F. Phosphorylation of beta III-tubulin. Biochemistry. 1996 Mar 26;35(12):3704–3711. doi: 10.1021/bi951247p. [DOI] [PubMed] [Google Scholar]
  27. Khandjian E. W., Méric C. A procedure for Northern blot analysis of native RNA. Anal Biochem. 1986 Nov 15;159(1):227–232. doi: 10.1016/0003-2697(86)90332-5. [DOI] [PubMed] [Google Scholar]
  28. Kuo D. Y., Mallick S., Shen H. J., DeVictoria C., Jones J., Fields A. L., Goldberg G. L., Runowicz C. D., Horwitz S. B. Analysis of MDR1 expression in normal and malignant endometrium by reverse transcription-polymerase chain reaction and immunohistochemistry. Clin Cancer Res. 1996 Dec;2(12):1981–1992. [PubMed] [Google Scholar]
  29. Laferrière N. B., Brown D. L. Effects of taxol on the polymerization and posttranslational modification of class III beta-tubulin in P19 embryonal carcinoma cells. Biochem Cell Biol. 1995 Sep-Oct;73(9-10):687–694. doi: 10.1139/o95-076. [DOI] [PubMed] [Google Scholar]
  30. Lewis S. A., Gilmartin M. E., Hall J. L., Cowan N. J. Three expressed sequences within the human beta-tubulin multigene family each define a distinct isotype. J Mol Biol. 1985 Mar 5;182(1):11–20. doi: 10.1016/0022-2836(85)90023-3. [DOI] [PubMed] [Google Scholar]
  31. Lewis S. A., Gu W., Cowan N. J. Free intermingling of mammalian beta-tubulin isotypes among functionally distinct microtubules. Cell. 1987 May 22;49(4):539–548. doi: 10.1016/0092-8674(87)90456-9. [DOI] [PubMed] [Google Scholar]
  32. Lewis S. A., Lee M. G., Cowan N. J. Five mouse tubulin isotypes and their regulated expression during development. J Cell Biol. 1985 Sep;101(3):852–861. doi: 10.1083/jcb.101.3.852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Lu Q., Luduena R. F. Removal of beta III isotype enhances taxol induced microtubule assembly. Cell Struct Funct. 1993 Jun;18(3):173–182. doi: 10.1247/csf.18.173. [DOI] [PubMed] [Google Scholar]
  34. Ludueña R. F. Are tubulin isotypes functionally significant. Mol Biol Cell. 1993 May;4(5):445–457. doi: 10.1091/mbc.4.5.445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Mary J., Redeker V., Le Caer J. P., Promé J. C., Rossier J. Class I and IVa beta-tubulin isotypes expressed in adult mouse brain are glutamylated. FEBS Lett. 1994 Oct 10;353(1):89–94. doi: 10.1016/0014-5793(94)01018-8. [DOI] [PubMed] [Google Scholar]
  36. McGuire W. P., Hoskins W. J., Brady M. F., Kucera P. R., Partridge E. E., Look K. Y., Clarke-Pearson D. L., Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996 Jan 4;334(1):1–6. doi: 10.1056/NEJM199601043340101. [DOI] [PubMed] [Google Scholar]
  37. McGuire W. P., Rowinsky E. K., Rosenshein N. B., Grumbine F. C., Ettinger D. S., Armstrong D. K., Donehower R. C. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989 Aug 15;111(4):273–279. doi: 10.7326/0003-4819-111-4-273. [DOI] [PubMed] [Google Scholar]
  38. Minotti A. M., Barlow S. B., Cabral F. Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem. 1991 Feb 25;266(6):3987–3994. [PubMed] [Google Scholar]
  39. Murdoch W. J. Ovarian surface epithelium, ovulation and carcinogenesis. Biol Rev Camb Philos Soc. 1996 Nov;71(4):529–543. doi: 10.1111/j.1469-185x.1996.tb01283.x. [DOI] [PubMed] [Google Scholar]
  40. Murphy W. K., Fossella F. V., Winn R. J., Shin D. M., Hynes H. E., Gross H. M., Davilla E., Leimert J., Dhingra H., Raber M. N. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst. 1993 Mar 3;85(5):384–388. doi: 10.1093/jnci/85.5.384. [DOI] [PubMed] [Google Scholar]
  41. Noonan K. E., Beck C., Holzmayer T. A., Chin J. E., Wunder J. S., Andrulis I. L., Gazdar A. F., Willman C. L., Griffith B., Von Hoff D. D. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A. 1990 Sep;87(18):7160–7164. doi: 10.1073/pnas.87.18.7160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Ohta S., Nishio K., Kubota N., Ohmori T., Funayama Y., Ohira T., Nakajima H., Adachi M., Saijo N. Characterization of a taxol-resistant human small-cell lung cancer cell line. Jpn J Cancer Res. 1994 Mar;85(3):290–297. doi: 10.1111/j.1349-7006.1994.tb02096.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Panda D., Miller H. P., Banerjee A., Ludueña R. F., Wilson L. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11358–11362. doi: 10.1073/pnas.91.24.11358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Parker S. L., Tong T., Bolden S., Wingo P. A. Cancer statistics, 1996. CA Cancer J Clin. 1996 Jan-Feb;46(1):5–27. doi: 10.3322/canjclin.46.1.5. [DOI] [PubMed] [Google Scholar]
  45. Ranganathan S., Dexter D. W., Benetatos C. A., Chapman A. E., Tew K. D., Hudes G. R. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res. 1996 Jun 1;56(11):2584–2589. [PubMed] [Google Scholar]
  46. Rao S., Orr G. A., Chaudhary A. G., Kingston D. G., Horwitz S. B. Characterization of the taxol binding site on the microtubule. 2-(m-Azidobenzoyl)taxol photolabels a peptide (amino acids 217-231) of beta-tubulin. J Biol Chem. 1995 Sep 1;270(35):20235–20238. doi: 10.1074/jbc.270.35.20235. [DOI] [PubMed] [Google Scholar]
  47. Roy S. N., Horwitz S. B. A phosphoglycoprotein associated with taxol resistance in J774.2 cells. Cancer Res. 1985 Aug;45(8):3856–3863. [PubMed] [Google Scholar]
  48. Rüdiger M., Plessman U., Klöppel K. D., Wehland J., Weber K. Class II tubulin, the major brain beta tubulin isotype is polyglutamylated on glutamic acid residue 435. FEBS Lett. 1992 Aug 10;308(1):101–105. doi: 10.1016/0014-5793(92)81061-p. [DOI] [PubMed] [Google Scholar]
  49. Schiff P. B., Horwitz S. B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A. 1980 Mar;77(3):1561–1565. doi: 10.1073/pnas.77.3.1561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Sullivan K. F., Cleveland D. W. Identification of conserved isotype-defining variable region sequences for four vertebrate beta tubulin polypeptide classes. Proc Natl Acad Sci U S A. 1986 Jun;83(12):4327–4331. doi: 10.1073/pnas.83.12.4327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Sullivan K. F. Structure and utilization of tubulin isotypes. Annu Rev Cell Biol. 1988;4:687–716. doi: 10.1146/annurev.cb.04.110188.003351. [DOI] [PubMed] [Google Scholar]
  52. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Wang D., Villasante A., Lewis S. A., Cowan N. J. The mammalian beta-tubulin repertoire: hematopoietic expression of a novel, heterologous beta-tubulin isotype. J Cell Biol. 1986 Nov;103(5):1903–1910. doi: 10.1083/jcb.103.5.1903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Wani M. C., Taylor H. L., Wall M. E., Coggon P., McPhail A. T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971 May 5;93(9):2325–2327. doi: 10.1021/ja00738a045. [DOI] [PubMed] [Google Scholar]
  55. Weinstein B., Solomon F. Phenotypic consequences of tubulin overproduction in Saccharomyces cerevisiae: differences between alpha-tubulin and beta-tubulin. Mol Cell Biol. 1990 Oct;10(10):5295–5304. doi: 10.1128/mcb.10.10.5295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Zaman G. J., Flens M. J., van Leusden M. R., de Haas M., Mülder H. S., Lankelma J., Pinedo H. M., Scheper R. J., Baas F., Broxterman H. J. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8822–8826. doi: 10.1073/pnas.91.19.8822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. van der Zee A. G., Hollema H. H., de Bruijn H. W., Willemse P. H., Boonstra H., Mulder N. H., Aalders J. G., de Vries E. G. Cell biological markers of drug resistance in ovarian carcinoma. Gynecol Oncol. 1995 Aug;58(2):165–178. doi: 10.1006/gyno.1995.1205. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES